Building a combination platform for new antimalarial combination therapies

Chair: Jörg J. Möhrle, MMV, Switzerland
Co-Chair: James McCarthy, QIMR Berghofer Medical Research Institute, Australia

Speakers and topics:
- Developing a combination tool for *in silico* assessment of antimalarial drug partnering, Nicole Andenmatten, MMV, Switzerland
- Combination studies in *P. falciparum* infected, humanized SCID mice, Inigo Angulo-Barturen, The Art of Discovery (TAD), Spain
- Characterisation of new antimalarial combinations in induced blood stage malaria studies, James McCarthy, QIMR Berghofer Medical Research Institute, Australia
- Model-informed drug development for antimalarial combination therapies, Ping Zhao, Bill & Melinda Gates Foundation, USA

Malaria: pre-clinical and clinical drug development tools, novel approaches and new candidates

Co-Chair: Francisco-Javier Gamo, DDW, GlaxoSmithKline, Spain
Co-Chair: Caroline Ng, University of Nebraska Medical Center, USA

736 A human 3D cell-based platform for drug discovery targeting *Plasmodium* hepatic infection, Catarina Brito, iBET, Portugal

737 Proteasome inhibitor-based combination therapy potently inhibits artemisinin-resistant *Plasmodium falciparum*, Caroline L. Ng, University of Nebraska Medical Center, USA

738 Antimalarial pyrrolidinamides fast-acting compounds with a novel mode of action, Laura M. Sanz, GlaxoSmithKline, Spain

739 A randomized controlled trial comparing parasite clearance profiles after single dose artesunate among subjects experimentally infected with artemisinin-resistant or artemisinin-sensitive *Plasmodium falciparum* parasites, Maria Rebelo, QIMR Berghofer Medical Research Institute, Australia, MMV co-authors: Stephan Chalon and Jörg J. Möhrle

740 SJ733, An oral inhibitor of PFA TP4 combined with a pharmacokinetic enhancer (CYP3A inhibitor): a novel approach in antimalarial drug development, Aditya H. Gaur, St. Jude Children’s Research Hospital, USA, MMV co-authors: Andrew Slade and Stephan Chalon

741 KAF156 and LUM-SDF combination phase 2 study pharmacokinetic run-in cohort results, Cornelis Winnips, Novartis, Switzerland, MMV co-author: Sophie Biguenet

742 Pharmacogenetics of the IVERMAL Trial: human metabolic genes and mosquito mortality response to high-dose ivermectin co-administered with dihydroartemisinin-piperaquine, Menno R. Smit, Liverpool School of Tropical Medicine, UK
Symposium 145
Sheraton, Rodrigue Gallery, 1st floor
Wednesday, 31 Oct., 4.00 pm – 5.45 pm

Supporting quality and child-friendly malaria interventions
Chair: Pierre Hugo, MMV, Switzerland
Co-Chair: Martin de Smet, Médecins Sans Frontières, Belgium

Speakers and topics:
- Ensuring a conducive environment for the introduction of quality, child-friendly medication, Suzanne Hill, WHO, Switzerland
- Reducing the malaria burden in community settings: synergism across varying transmission settings, Elizabeth Chizema, Ministry of Health, Zambia
- Management of severe malaria cases: learnings and challenges from the field, Manuel Hetzel, Swiss Tropical and Public Health Institute, Switzerland
- Severe malaria rapid assessments: knowledge, attitudes and practices, Tendayi Kureya, Development Data, Zimbabwe
Poster sessions

Marriott, Grand Ballroom, 3rd floor
Monday, 29 Oct., 12.00 pm – 1.45 pm

**Poster Session A: Presentations and light lunch**

302 Antimalarial pantothenamide metabolites target acetyl-CoA synthesis in *Plasmodium falciparum*, Koen Dechering, TropIQ Health Sciences, Netherlands, MMV co-author: Brice Campo

LB-5058 Proguanil- old drugs new tricks, Kathy Andrews, Griffith University, Australia, MMV co-author: Jeremy Burrows

Marriott, Grand Ballroom, 3rd floor
Tuesday, 30 Oct., 12.00 pm – 1.45 pm

**Poster Session B: Presentations and light lunch**

996 The ex vivo growth profile of artemisinin-resistant parasites after artesunate treatment in the induced blood stage malaria model, Maria Rebelo, QIMR Berghofer Medical Research Institute, Australia, MMV co-author: Jörg J. Möhrle

LB-5232 Discovery of new drug leads for malaria chemoprevention, Katherine Andrews, Griffith University, Australia, MMV co-author: Jeremy Burrows

Marriott, Grand Ballroom, 3rd floor
Wednesday, 31 Oct., 12.00 pm – 1.45 pm

**Poster Session C: Presentations and light lunch**

LB-5534 Pregnancy outcomes in women exposed to dihydroartemisinin-piperaquine during the first trimester of pregnancy in Indonesia – a retrospective record linkage study, Rukhsana Ahmed, Liverpool School of Tropical Medicine, UK, MMV co-author: André-Marie Tchouatieu

1703 Drug sensitivities and mechanisms of resistance in Ugandan *Plasmodium falciparum* isolates to lead antimalarials in the Medicines for Malaria Venture development pipeline, Stephanie A. Rasmussen, Dominican University of California, USA, MMV co-author: Benjamin Blasco

1704 Identification of a dual liver-axial stage antimalarial targeting PfDHODH, Amanda K. Lukens, The Broad Institute, USA, MMV co-authors: Brice Campo, Jeremy Burrows and Melanie Rouillier

1734 Impact of CYP2D6 on primaquine and tafenoquine efficacy in *Plasmodium vivax* malaria phase 3 clinical trials, Pamela St. Jean, PAREXEL International Corp, USA, MMV co-author: Stephan Duparc

1736 Haemoglobin decline in G6PD normal *P. vivax* patients treated with chloroquine and tafenoquine or primaquine in the phase 3 TAF112582 (DETECTIVE) study, Khadeejah Mohamed, GlaxoSmithKline, UK, MMV co-author: Stephan Duparc

1812 Health worker’s post-training practices for case management of severe malaria in southern Nigeria, Olatunde M. Adesoro, Malaria Consortium, Nigeria, MMV co-author: Alexis Kamdjou